Europe’s market for Treponema pallidum tests is expected to experience sustained growth over the coming decade, fueled by the resurgence of syphilis cases, increasing emphasis on early diagnosis, and strengthened sexually transmitted infection (STI) surveillance programs across the region.

According to GlobalData’s latest report, “Treponema Pallidum Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036,” Europe represented nearly 30% of the global Treponema pallidum testing market in 2025. The market is projected to expand at a compound annual growth rate (CAGR) of approximately 3% through 2036.

The growing prevalence of syphilis in several European countries is driving demand for timely and accurate diagnostic solutions. Healthcare providers and public health authorities are increasingly prioritizing early disease detection and intervention to reduce transmission rates and prevent long-term complications associated with untreated infections.  

Sarvesh Kumar, Medical Devices Analyst at GlobalData, comments: “Europe’s Treponema pallidum tests market is gaining momentum as healthcare systems increasingly recognize the importance of early syphilis diagnosis in reducing long-term complications and transmission risks. The growing focus on preventive screening, particularly among high-risk and vulnerable populations, alongside expanding diagnostic accessibility, is expected to strengthen testing demand across the region.” 

Congenital syphilis continues to pose a significant public health challenge due to its association with severe neonatal health complications and avoidable adverse pregnancy outcomes. In response, healthcare authorities across Europe are placing greater emphasis on prenatal screening, disease surveillance, and timely treatment interventions to limit transmission and improve maternal and child health outcomes.

These initiatives are expected to further accelerate demand for Treponema pallidum testing across both clinical and public health settings, reinforcing the role of diagnostic tools in supporting disease control strategies.

Kumar concludes: “While access to timely syphilis testing remains uneven in parts of Europe, the growing urgency around syphilis control and stronger focus on early diagnosis and timely intervention are expected to support the long-term expansion of the Treponema pallidum tests market in the region.